About
Joe coordinates the discovery, validation, and translation of therapeutic targets related to human diseases of aging, integrating computational analyses of large-scale datasets and experimental model systems.
Before joining Calico, Joe served as Chief Scientific Officer and Head of Research and Development at Sonoma Biotherapeutics from 2023 to 2026, where he oversaw the development of engineered regulatory T cell therapies for autoimmune diseases. From 2021 to 2023, Joe directed discovery and translation of therapeutic targets related to human genetic variation as Chief Scientific Officer at 23andMe Therapeutics. At Genentech from 2006 to 2021, Joe led a laboratory that conducted translational research in respiratory diseases, contributing to multiple therapeutic targets and over 75 publications, and directed target discovery for the Immunology and Ophthalmology therapeutic areas as Vice President and Senior Fellow.
Education:
- Postdoc in Pathology and Developmental Biology, Stanford University School of Medicine
- M.D., Weill Medical College of Cornell University
- Ph.D., The Rockefeller University
- A.B. in Chemistry, Princeton University